178 related articles for article (PubMed ID: 38182581)
1. Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer's disease.
Van Hulle C; Ince S; Okonkwo OC; Bendlin BB; Johnson SC; Carlsson CM; Asthana S; Love S; Blennow K; Zetterberg H; Scott Miners J
Transl Psychiatry; 2024 Jan; 14(1):3. PubMed ID: 38182581
[TBL] [Abstract][Full Text] [Related]
2. Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer's disease.
Miners J; van Hulle C; Ince S; Jonaitis E; Okonkwo OC; Bendlin B; Johnson S; Carlsson C; Asthana S; Love S; Blennow K; Zetterberg H
Res Sq; 2023 Apr; ():. PubMed ID: 37131622
[TBL] [Abstract][Full Text] [Related]
3. CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology.
Miners JS; Kehoe PG; Love S; Zetterberg H; Blennow K
Alzheimers Res Ther; 2019 Sep; 11(1):81. PubMed ID: 31521199
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease.
Kehoe PG; Al Mulhim N; Zetterberg H; Blennow K; Miners JS
J Alzheimers Dis; 2019; 72(2):525-535. PubMed ID: 31594235
[TBL] [Abstract][Full Text] [Related]
5. Changes in CSF sPDGFRβ level and their association with blood-brain barrier breakdown in Alzheimer's disease with or without small cerebrovascular lesions.
Lv X; Zhang M; Cheng Z; Wang Q; Wang P; Xie Q; Ni M; Shen Y; Tang Q; Gao F;
Alzheimers Res Ther; 2023 Mar; 15(1):51. PubMed ID: 36915135
[TBL] [Abstract][Full Text] [Related]
6. Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers.
Wang J; Fan DY; Li HY; He CY; Shen YY; Zeng GH; Chen DW; Yi X; Ma YH; Yu JT; Wang YJ
Mol Neurodegener; 2022 Jan; 17(1):9. PubMed ID: 35033164
[TBL] [Abstract][Full Text] [Related]
7. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
[TBL] [Abstract][Full Text] [Related]
8. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
[TBL] [Abstract][Full Text] [Related]
10. Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.
Cicognola C; Mattsson-Carlgren N; van Westen D; Zetterberg H; Blennow K; Palmqvist S; Ahmadi K; Strandberg O; Stomrud E; Janelidze S; Hansson O
Neurology; 2023 Jul; 101(1):e30-e39. PubMed ID: 37137722
[TBL] [Abstract][Full Text] [Related]
11. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
12. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
[TBL] [Abstract][Full Text] [Related]
13. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
14. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
[TBL] [Abstract][Full Text] [Related]
15. Glial activation and inflammation along the Alzheimer's disease continuum.
Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
[TBL] [Abstract][Full Text] [Related]
16. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
Simrén J; Brum WS; Ashton NJ; Benedet AL; Karikari TK; Kvartsberg H; Sjons E; Lussier FZ; Chamoun M; Stevenson J; Hopewell R; Pallen V; Ye K; Pascoal TA; Zetterberg H; Rosa-Neto P; Blennow K
Alzheimers Res Ther; 2022 Dec; 14(1):192. PubMed ID: 36544221
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.
Janelidze S; Hertze J; Zetterberg H; Landqvist Waldö M; Santillo A; Blennow K; Hansson O
Ann Clin Transl Neurol; 2016 Jan; 3(1):12-20. PubMed ID: 26783546
[TBL] [Abstract][Full Text] [Related]
18. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
[TBL] [Abstract][Full Text] [Related]
19. The Relationship between Markers of Inflammation and Degeneration in the Central Nervous System and the Blood-Brain Barrier Impairment in Alzheimer's Disease.
Muszyński P; Kulczyńska-Przybik A; Borawska R; Litman-Zawadzka A; Słowik A; Klimkowicz-Mrowiec A; Pera J; Dziedzic T; Mroczko B
J Alzheimers Dis; 2017; 59(3):903-912. PubMed ID: 28697565
[TBL] [Abstract][Full Text] [Related]
20. sPDGFRβ and neuroinflammation are associated with AD biomarkers and differ by race: The ASCEND Study.
Butts B; Huang H; Hu WT; Kehoe PG; Miners JS; Verble DD; Zetterberg H; Zhao L; Trotti LM; Benameur K; Scorr LM; Wharton W
Alzheimers Dement; 2024 Feb; 20(2):1175-1189. PubMed ID: 37933404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
